SCHEMBL830006

SCHEMBL830006

CCOC(=O)c1cccc(F)c1F

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.63
CES2 O00748 1/20 0.55
BCHE P06276 1/20 0.55
CES1 P23141 1/20 0.55
ALDH1A1 P00352 3/20 0.54
HSD17B10 Q99714 2/20 0.54
TDP1 Q9NUW8 2/20 0.52
TP53 P04637 1/20 0.52
HTT P42858 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
KDM4E B2RXH2 3/20 0.51
GLA P06280 1/20 0.51
GAA P10253 1/20 0.51
HPGD P15428 1/20 0.51
CDC25B P30305 2/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isopropylamine SCHEMBL27585721 0.92 TSHR (0.54) TSHRCES2BCHECES1ALDH1A1
SCHEMBL7467330 0.91 TSHR (0.70) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL23817273 0.87 CES2 (0.49) TSHRCES2BCHECES1ALDH1A1
SCHEMBL14992393 0.86 TSHR (0.63) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL5248806 0.86 TSHR (0.63) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL2325118 0.85 TSHR (0.74) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL29604433 0.85 TSHR (0.74) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL18867935 0.85 TSHR (0.74) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL1958113 0.85 TSHR (0.57) TSHRCES2CES1ALDH1A1HSD17B10
SCHEMBL7728983 0.84 CA12 (0.62) TSHRALDH1A1HSD17B10TDP1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117946303-A Catalyst, preparation method thereof, method for regulating and controlling ethylene polymerization kinetics behavior and application 中国石油化工股份有限公司 2024-04-30 CN claimed
CN-114865080-A Lithium ion battery electrolyte and lithium ion battery 香河昆仑新能源材料股份有限公司 2022-08-05 CN claimed
CN-108794505-A A kind of preparation method of benzheterocycle 南京齐正化学有限公司 2018-11-13 CN claimed
CN-108218668-A A kind of restoring method of 2,6 difluoro-benzoic acid ethyl esters 南京齐正化学有限公司 2018-06-29 CN claimed
CN-102344419-A Preparation method of broad-spectrum antifungal drug fluconazole ZHEJIANG GENEBEST PHARMACEUTICAL CO LTD 2012-02-08 CN claimed
CN-117946303-A Catalyst, preparation method thereof, method for regulating and controlling ethylene polymerization kinetics behavior and application 中国石油化工股份有限公司 2024-04-30 CN disclosed
CN-117946304-A Spherical catalyst component containing fluoroester electron donor, preparation method, catalyst and application thereof in ethylene polymerization 中国石油化工股份有限公司 2024-04-30 CN disclosed
US-20230121721-A1 MONOACYLGLYCEROL LIPASE INHIBITORS STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) 2023-04-20 US disclosed
EP-4114829-A1 MONOACYLGLYCEROL LIPASE INHIBITORS Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) 2023-01-11 EP disclosed
CN-114865080-A Lithium ion battery electrolyte and lithium ion battery 香河昆仑新能源材料股份有限公司 2022-08-05 CN disclosed
EP-3875452-A1 MONOACYLGLYCEROL LIPASE INHIBITORS Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) 2021-09-08 EP disclosed
CN-110167926-A POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS 米托布里奇公司 2019-08-23 CN disclosed
CN-1137884-C Indazole compounds and pharmaceutical compositions that inhibit protein kinases and methods of use thereof ������ҩ�����޹�˾ 2004-02-11 CN disclosed
CN-1425008-A 3-aminoquinazolin-2, 4-dione antibacterial agents WARNER LAMBERT CO (US) 2003-06-18 CN disclosed
US-6534524-B1 Antiproliferative agents, including axitinib AGOURON PHARMACEUTICALS, INC. 2003-03-18 US disclosed
US-6531491-B1 Methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, AGOURON PHARAMACEUTICALS, INC. 2003-03-11 US disclosed
CN-1374950-A Indazole compounds and pharmaceutical compositions for inhibiting protein kinases and their use AGOURON PHARMACETUICALS INC (US) 2002-10-16 CN disclosed
EP-1218348-A2 INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE AGOURON PHARMACEUTICALS, INC. (US) 2002-07-03 EP disclosed
WO-2001002369-A2 INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE AGOURON PHARMACEUTICALS, INC. (US) 2001-01-11 WO disclosed
CN-1137271-A 4-benzoylisoxazoles and their use as herbicides RHONE POULENC AGRICULTURE (GB) 1996-12-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121721-A1 MONOACYLGLYCEROL LIPASE INHIBITORS MGLL, PNLIP, LIPA TSHR 4078/4885CES2 64/4885BCHE 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.